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Results: Inhibition of 5/~M ADP-tnduced platefet aggr~on showed a 
trend towards a dos@relationship over lhe dose-range tested. Bleeding time 
prolongation factor never exceeded 2. Tolerance was good at all doses 
tosteoL 
Cond~:  In this muiticontor d~.e-mnge study in athe~scle~dio pa~nts, 
~ 1  demonstrated a c~mlat~ activity. The dose of 75 mg once 
daily was chosen for the phase III Interest/anal study CAPRIE (CIopid~grel 
vs, Aspidn In Patients at Risk of isohamto Events) currently on-going in over 
19,o00 patients, 
~ ~dety  of the Combination of Oral Anticoagulant 
end Antlplatelet Therapy In Cordlovascular 
Disease: A Mats*Analysis 
Fresk W.A. Vetheugt. Department of CardiolOgy, UnivemtO, Hospital 
Nijmegen, Nijmegen, The Netherlands 
Both oral anticoagulant (AC) and antipfatolet (AP) therapy are effective in 
redu~ng mortality in patients (ptS) w~h oardtovas¢~ar disease. The outcome 
Of the trials of combined AC,/AP compared to AC alone, AP alone or placebo 
is promising, but its s~ety Is a matter of con(~em, 
In the 6 published tdals of combined AC/AP directly comparing reference 
therapy (AC, AP or placate) 4,874 p~ were randomized. High intensity AC 
(AC) INR >.>. 2 5 was combined with high (>_ 500 mg asptdn op') dose AP (AP) 
in 3 ldals, and with low (_< 100 mg aspirin qd) dose AP (ap) in 2 trials. Low 
Intensity AC (a¢) INR ~ 2.5 was Combined with ap in 4 trials. Major bleeding 
(95% el): 
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~ W h e d  Should Be the Goal of LOL~Cholesterol 
Loweflng in Comn~ Patients; a Fixed Level or a 
~roent  Redu~tion? 
David Wets*s, Jus~ne Hollyer, Gilbert R. Thompson. Hartford Hospital, 
Hartford, C T; Hammersmi~ Hospital, Lanai, UK 
NCEP guidelines stipulate that LOL.~totsste~! (LDL-C) should be reduced to 
the same level in all coronary patterds, to ~ 100 mg/dl. But a recent secondary 
analysis of the 4S data showed that the decrease in LDL.-C with almvestatin 
(32-o~7%) and the do<~ease in relative risk (32~)  were o~mpera~e 
across all q~m~tiles of baseline LDL-C, despite d~emnoes in ~dat  LDL-C 
(Lancet 1995;345,1274). To test the hypothesis that the reduction in LOL-C 
cognates better with outcome than the on-treatment level of I.CL-C, we ex. 
stained the 24 control and treatment greups from the 11 ¢gnotesterol4owedng 
comna~ ang iog~ trials (FATS, SCOR, STARS, Lifestyle, MARS, CCNT, 
HARP, SCRIP, ~ ,  FHRS and PLAC-1) with quan~tative measurements 
of lesion percent diametor stenosls cllange (&%DS). Mean A%DS ranged 
from +5,8 (prog~P'~ton) to -2.5 (regression), mean on.lxial LDL-C varied 
from 86 to 242 rag/tit reel change in LDL-C ranged from +3% tO -53%. Un- 
~r  :~essio, an~s~ was I~tom~ w~ ~e groups weighted ~ng 
to their size. 
Resutts: The relationship between omffial LDL-C levels and &%OS was 
we~k; r= 0.36, p = 0.086. However, a strong mlntionship was seen between 
% change in LDL-C and &%DS t~.%DS = 3.18 + 0.071 x %&LOL-C; r = 
O.?~. p < 0 .~.  Acoordlng to the equation, ~ 44% reduction of LDL-C is 
needed to arrest comr~y progression. 
Conc/L~s/ons: Redualng LDL-d,~Olesterol by a percentage from the baseline 
level ~ to be a more reasonab~,e goal in comrade, patients than aiming 
for ~e same target svel in all. The emphasis on ta~ levets in the current 
(~l inOs seems open to question. 
A~/I~P A%ip i l lhi= AC 1¢ lip pl l¢tbo 
¢ombln~ I l tmt~gtl  mfereaee ~/e¢  
Thus, combined low intensity oral an,coagulanUIow dose aspidn therapy 
shows the lowest major bleeding (5/100 pt ym). not significantly ditterent fp.~.~ 
low Intensity oral anticoagulant l[ ~erapy alone. This combination therapy now 
undergoes large s(~e evaluation of clini~d efficacy and safety. 
~ Enhanced VuoeonsM~tlon to Coronary 
EndothellmB R~mpt~s  Actlvaffon In Experimental 
Congestive Heart Failure 
Chades R. Cannan. John C. Bumett Jr.. Amir Lemlan. ~ Clin~ 
Rochester. MN 
Thorad¢ Inferior vans cava constriction (TiVCC) ts an experimental modal of 
heart failure ~aracterlzed by a decrease in cardiac output and an Ircmase 
in plasma endothelle (ET) consentretisRs, ET, a cor011ary vesoconstifctor0 
mediates its activity through two specific receptors (ET-A and ET-B), which 
demenstmte d~fferont activity levers in pa~'~jslotogl~ mndtions. The 
eumant study was designed to test the hypothesis that e~le . fa l  heart 
fallura is char~"torized by an enhanced coronary vaso¢0~ to the ET- 
B receptors aoflvaflon. Sarafotoxin (an ET-B receptor ngo,~) ~t 2 ng4~/mfn 
was infused into the left ci=mtmlflex corona~ s#ts~j In nomlal (n = 5) and 
"nVCG (n - 5) ~mthe~ dogs. Plasma ET was alevated in me TNCC 
doge aS c~npamd to lhe Norrnal group (37 ~ 5 vs. 17 ~: 3, p < 0.05) 
~vcG 
%& CBF -~"~ 8 -31 ~4"  
%&CVR 12~B 53::1=12" 
% A CAO 1.g~0.7 2.1 -~ 1.O 
Thesa atudiss 0~m~nWate m enhemO~ mxo~y w ~  ~- 
spoese to sa turn  In exper~-c,,.-,-,;al hea~ ~ ~ is ~ iscaea~o 
to l~,e ~ '1'his StUdy ~ ,  an ~a~,~n is. om:~at'y ET-B 
mcel~o~ in s~ m~l  ~ ~,~ay  vascu~ ~ this m~i~ 
• Phyedc!an Compllanc:e W'dh National Cholesterol 
Educ~$~r= Panel Guldelimm in Patients With 
Myoeardlal Infarction 
Od Ben.Yehuda. Parul Oesal. Oardel G. Blarchatd. University of CaJifomia, 
San D~o, C~ 
Lowedng elevated LDL-Cbelestorol (LOL-C) i. patterns with documented 
CAD reduces morbidity and moflality. NGEP ggide!inss in this pepulalJon 
are ba~ed on LDL-C levels, with a largat level of < 100 rag/all. In order to 
3ssess physician compliarce with NCEP guidelinss, we ~ tt~ cam 
of all p~tients under 75 years of age dischm'ged with the dlagr<e.;is of acute 
MI in 1994 in our institution. Mean fallow.up was 9.6 :t: 0.8, months (ra~"e 
4-15), 
Of 114 patients with tha diagn~ls of acute MI, 30 (26%} had known byper 
LL~.C pdor to thalr Ml Of these only 6/30 (20%} had doomlantad LDL.C h ~ 
the t~get range on foll0w-Up. In 7/30 (23%) no therapy ~ inslituted, while in 
17/30 (57%) taq~t LOL-C level was either not acJlleved or not documented, 
Of the 84 patients (74%) witbe~ knoml I l yped i~ six had evaluation 
and therapy per NCEP gtddetinas. An tn¢0mpie~ evaluation (only total.C or 
pror~ obtained o'~eg e~te tansy) was ~ in 44t84 (S,W,,) wh,e 
16/84 (19%) had no lipld evakm~on ~ ~11, No theral~ was inatitutod In 18/84 
(21%) wha met NGEP cdtoda tot therapy. 
Overafl. only 12/114 (11%) i~tlerds were evaluated ~ to NCEP 
~ and r~d docume,'~on of~ m~tmr, t ~ .  m contres~ 
100% Of paf~ontS were ~ ASA (i) < 0.001), another ecommanded 
tbempy in ~k~ts w~, CAD. 
1"firm physk~an ¢or~ ~ NGEP guidelines in mm study was low, 
w~h most patha~ not having LDL-C bas~ ~ and themw. Greater 
ChdSl~ M, Bat~,  M. StewaR West, Su2anne M. Jaax, lylnno W. Scott, 
J. Ala~ He~l, Pe~ir H, Joi-~,~, John A. Fanlter, Antonio M. Gotto, Jr.. Bayto¢ 
corm of M~x~Ve. Hous=~ TX 
lyre ~993 NCEP reomm'oends th= de~'~ (Stop. Oie9 ~ t~ed ~ 
~p m t~ wk in ~ ad~ts w~h Clio ~ a¢~eve ~r  LDL~ go~ al 
~ . -~;~ ~ dm from the ~ ~  
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